Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 3:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Class IV Angina Clear all
Not listed Phase 1Phase 2 Interventional

Biomarker Study: Heart Failure Patients at Risk

NCT05336175
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Angiotensin 1-7, Saline solution
Drug
Lead sponsor
University of Arizona
Other
Eligibility
45 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Jun 26, 2026, 3:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

NCT05938725
View directory record Official record
Conditions
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Interventions
KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
Biological · Drug
Lead sponsor
Kyverna Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Completed No phase listed Observational Results available

Cardiogenesis Transmyocardial Revascularization Registry

NCT01827319
View directory record Official record
Conditions
Class IV Angina
Interventions
Not listed
Lead sponsor
Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
24
States / cities
Tuscon, Arizona • Bakersfield, California • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Jun 26, 2026, 3:44 AM EDT
Active, not recruiting Early Phase 1 Interventional

Mechanistic Studies of Nicotinamide Riboside in Human Heart Failure

NCT04528004
View directory record Official record
Conditions
Heart Failure, Systolic, Heart Failure NYHA Class IV, Metabolic Disturbance
Interventions
Nicotinamide riboside, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional Results available

C-Pulse IDE Feasibility Study- A Heart Assist System

NCT00815880
View directory record Official record
Conditions
Heart Failure
Interventions
C-Pulse™ (Implantable Counterpulsation Therapy)
Device
Lead sponsor
Nuwellis, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
6
States / cities
Birmingham, Alabama • Louisville, Kentucky • Saint Paul, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional Results available

Hemodynamic-GUIDEd Management of Heart Failure

NCT03387813
View directory record Official record
Conditions
Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
Interventions
CardioMEMS™ HF System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
125
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of ONT01 in Lupus

NCT07107659
View directory record Official record
Conditions
Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus, SLE, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (Disorder)
Interventions
ONT01 is a small molecule CD11b modulator.
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional Results available

Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C

NCT01381172
View directory record Official record
Conditions
NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Interventions
Optimizer System, No intervention: Optimal medical therapy
Device · Other
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
32
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional Results available

A Study to Improve Physician-Youth Communication and Medical Decision Making

NCT05835063
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
We Chatt communication tool, Usual/standard care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Not listed Not applicable Interventional

Painless Laser Therapy for Overactive Bladder

NCT01569061
View directory record Official record
Conditions
Overactive Bladder
Interventions
LCT-1000TM (Manufacturer: LiteCure)
Device
Lead sponsor
Zipper Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Jun 26, 2026, 3:44 AM EDT
Recruiting Not applicable Interventional

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

NCT02537769
View directory record Official record
Conditions
Tricuspid Regurgitation, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Left ventricular assist device (LVAD), Tricuspid Valve Repair (TVR)
Device · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Jun 26, 2026, 3:44 AM EDT
Active, not recruiting Phase 1 Interventional

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220
View directory record Official record
Conditions
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Interventions
AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Recruiting Not applicable Interventional

3M(TM) Filtek(TM) Supreme Flowable Composites for Class IV and Veneers

NCT07128589
View directory record Official record
Conditions
Dental Restoration, Dental Veneers
Interventions
3MTM FiltekTM Supreme Flowable Composite
Device
Lead sponsor
New York University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 26, 2026, 3:44 AM EDT
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

NCT06859970
View directory record Official record
Conditions
Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
Interventions
PAS-C System
Device
Lead sponsor
InterShunt Technologies, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Jonesboro, Arkansas • Thousand Oaks, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 26, 2026, 3:44 AM EDT
Terminated No phase listed Observational Results available

The PEARL 8.0 Post-Approval Study

NCT01845103
View directory record Official record
Conditions
Class IV Angina
Interventions
Not listed
Lead sponsor
Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jun 26, 2026, 3:44 AM EDT
Recruiting Phase 1 Interventional

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

NCT05647213
View directory record Official record
Conditions
Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
iPSC-CL
Biological
Lead sponsor
HeartWorks, Inc.
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 26, 2026, 3:44 AM EDT
Not listed Not applicable Interventional

Feasibility Study of the Intravascular Ventricular Assist System (iVAS)

NCT02645539
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
intravascular ventricular assist system (iVAS)
Device
Lead sponsor
NuPulseCV
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional Results available

Family Palliative and End-of-Life Care for Advanced Heart Failure

NCT04153890
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
FamPALcare
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jun 26, 2026, 3:44 AM EDT
Recruiting Not applicable Interventional

Sustaining Home Heart Failure Palliative Care in Rural Appalachia

NCT06791850
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
HF-FamPALhomeCARE
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
45 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Not applicable Interventional

Exergaming in Advanced HF With Multiple Chronic Conditions Prior to LVAD Implantation or Heart Transplant

NCT03580759
View directory record Official record
Conditions
Heart-Assist Devices, Heart Failure NYHA Class IV, Exercise Training
Interventions
PREHAB
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jun 26, 2026, 3:44 AM EDT
Not listed Phase 4 Interventional

Remission From Stage D Heart Failure

NCT01774656
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Pharmacological Treatment
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jun 26, 2026, 3:44 AM EDT
Completed Early Phase 1 Interventional Results available

Nicotinamide Riboside in LVAD Recipients

NCT03727646
View directory record Official record
Conditions
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
Interventions
Nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jun 26, 2026, 3:44 AM EDT
Completed No phase listed Observational

CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study

NCT02694861
View directory record Official record
Conditions
Class IV Angina
Interventions
Not listed
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Jun 26, 2026, 3:44 AM EDT